SOAT1 and Alzheimer disease: Immunomodulating biologic compounds have gained considerable traction for use in the treatment of AD, and recent studies have highlighted the janus kinase (JAK)-signal transducer and activation of transcription (STAT) signaling pathway as a target for drug development14.